Pages
(Move to ...)
Home
About me
▼
Thursday, August 24, 2023
The Nucleic Acid Therapeutics Race to Revolutionize Alpha-1-Antitrypsin
›
Alpha-1-antitrypsin disease (AATD) is caused by mutations in the SERPINA1 gene coding for alpha-1-antitrypsin (AAT). There are an estimate...
Monday, July 24, 2023
Lightning Fast Wave Life Sciences Demonstrates High ADAR Editing Rates Across Targets
›
There was a time, not that long ago, when 1-3% ADAR editing rates in tissue culture cells were typically reported in the field. The hope th...
Friday, July 14, 2023
Korro Bio To Become Third Publicly Listed ADAR Editing Company
›
Today, pure-play ADAR Editing Korro Bio announced that it will reverse merge into biotech shell Frequency Therapeutics (current ticker: FRE...
Saturday, April 29, 2023
Roche Impresses with Effective RNA Editing of Polyglutamine Repeat mRNA
›
Roche has shown interest in RNA Editing through its 2021 partnership with Shape Therapeutics. The goal of this partnership was to use Sha...
3 comments:
Wednesday, April 26, 2023
RNAi Also Conquers the Central Nervous System
›
In the span of a day, RNAi Therapeutics have gone from a mechanism widely viewed as being constrained to the liver only, to a major therapeu...
1 comment:
Tuesday, April 25, 2023
Oligonucleotides Break Through to the Lung
›
It is days like today that I live for . Days when new platform technology data is revealed that will change the practice of medicine and be...
3 comments:
Tuesday, April 4, 2023
ProQR and Partner Eli Lilly Demonstrate Oligonucleotide-induced RNA Editing in the CNS: A Major De-risking Event for the Industry
›
With every new oligonucleotide therapeutics modality that feeds into an endogenous cellular mechanism comes uncertainty as to whether the me...
›
Home
View web version